StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cantor Fitzgerald Expects StemCells (STEM) to Present GA Data This Week; Reiterates Buy
June 22, 2015 7:03 AM EDTCantor Fitzgerald reiterates a Buy rating and $2.00 price target on StemCells (NASDAQ: STEM) ahead of GA data that is anticipated to be Presented this week. Analyst Caroline Corner expects positive results, based on interim data.
Corner commented, "We anticipate that data will be... More
StemCells (STEM) Receives Approval from Health Canada to Expand Pathway Study
June 18, 2015 8:06 AM EDTStemCells (NASDAQ: STEM) announced that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human... More
